Insider Selling: Ned D. Segal Unloads 4,500 Shares of RPX Corp. Stock (RPXC)
RPX Corp. (NASDAQ:RPXC) CFO Ned D. Segal unloaded 4,500 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $15.16, for a total value of $68,220.00. Following the completion of the transaction, the chief financial officer now directly owns 39,801 shares in the company, valued at approximately $603,383. The transaction was disclosed in a filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Barclays downgraded shares of RPX Corp. from an “overweight” rating to an “equal weight” rating in a research note on Monday, August 4th. They now have a $17.00 price target on the stock, down previously from $20.00. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of RPX Corp. in a research note on Monday, July 21st. They now have a $19.00 price target on the stock, up previously from $18.50.
RPX Corp. (NASDAQ:RPXC) traded down 2.05% during mid-day trading on Thursday, hitting $14.79. The stock had a trading volume of 180,671 shares. RPX Corp. has a 52 week low of $14.55 and a 52 week high of $18.75. The stock has a 50-day moving average of $15.49 and a 200-day moving average of $16.27. The company has a market cap of $794.5 million and a price-to-earnings ratio of 23.89.
RPX Corp. (NASDAQ:RPXC) last released its earnings data on Tuesday, July 29th. The company reported $0.24 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.22 by $0.02. The company had revenue of $64.30 million for the quarter, compared to the consensus estimate of $63.72 million. During the same quarter last year, the company posted $0.26 earnings per share. RPX Corp.’s revenue was up 16.9% compared to the same quarter last year. On average, analysts predict that RPX Corp. will post $0.97 earnings per share for the current fiscal year.
RPX Corporation (NASDAQ:RPXC) provides patent risk management solutions, offering defensive buying, acquisition syndication, patent intelligence and advisory services.